{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-139180","form_type":"8-K","ticker":"HRGN","cik":"0001563665","company_name":"Harvard Apparatus Regenerative Technology, Inc.","filed_at":"2021-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.049608+00:00","generated_at":"2026-06-28T08:22:10.928863+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Biostage reports Q3 net loss of $0.8M; cash $2.0M, funds ops into Q2 2022","bullets":["Net loss for Q3 2021 was $0.8M ($0.8 per share) vs $0.7M ($0.07 per share) in Q3 2020.","Nine-month 2021 net loss of $2.1M ($0.22 per share) vs $3.8M ($0.45 per share) in prior comparable period.","Cash on-hand $2.0M as of Sep 30, 2021, up $1.5M from prior year.","Proceeds of $2.6M from private placements of 1.3M shares and warrants in first nine months of 2021.","Expects current cash to fund operating expenses and capex into Q2 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-139180","json":"https://secwatch.observer/filing/0001104659-21-139180.json","markdown":"https://secwatch.observer/filing/0001104659-21-139180.md","text":"https://secwatch.observer/filing/0001104659-21-139180.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563665/000110465921139180/0001104659-21-139180-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563665/000110465921139180/tm2132943d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T08:22:10.928863+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}